

ASX Announcement

15 January 2026

First OncoSil™ Treatment at Acibadem Maslak Hospital

Sydney, Australia – 15 January 2026: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce that the first OncoSil™ treatment has been successfully performed at Acibadem Maslak Hospital, Istanbul, Türkiye.

Acibadem Maslak Hospital is one of the flagship hospitals within the Acibadem Health Group, one of the largest and most reputable private healthcare providers in the region. Founded in 1991, Acibadem Health Group delivers healthcare services across 24 hospitals and 15 medical centres in 5 countries, supported by approximately 25,000 employees, including more than 3,500 physicians and 4,500 nurses. The Group adopts a comprehensive “360-degree” healthcare service model, encompassing hospitals, medical centres, affiliated support service companies, and Acibadem University.

The successful OncoSil™ treatment was performed on 14 January 2026 and represents an important milestone in the Company’s expansion across key international markets. Türkiye is a strategically significant market for OncoSil Medical, with approximately 8,500 new pancreatic cancer cases diagnosed each year, highlighting a substantial unmet clinical need. The country’s large patient population, strong private healthcare sector, and internationally recognised centres of clinical excellence – many of which attract both domestic and international patients – provide an important foundation for growth. Establishing clinical adoption at leading institutions such as Acibadem Maslak Hospital supports the Company’s strategy to build awareness, generate clinical momentum, and accelerate the uptake of OncoSil™ across Türkiye and the wider region, reinforcing its commitment to improving outcomes for patients with pancreatic cancer.

Professor Guralp Onur Ceyhan, HPB Surgeon at Acibadem Maslak Hospital, said:

“Pancreatic cancer remains one of the most challenging malignancies to treat, particularly in patients with locally advanced disease where surgical resection is not initially possible. Localised therapies can play an important role in this setting, as they offer the potential to control tumour growth while minimising systemic toxicity. Our aim is to use effective local treatments to downstage disease, allowing more patients to become eligible for surgical resection, which remains the only curative option. Innovative approaches such as OncoSil™ can provide an important addition to the multidisciplinary treatment strategy for patients with locally advanced pancreatic cancer.”

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

“The successful completion of the first OncoSil™ treatment at Acibadem Maslak Hospital is an important step forward for the Company and a clear validation of our clinical and commercial strategy. With around 8,500 new pancreatic cancer cases diagnosed annually, Türkiye represents a significant opportunity to address an area of high unmet medical need. From our experience, Türkiye is also a fast adopter of new medical

technologies, supported by a sophisticated healthcare system and highly skilled clinicians. Partnering with leading institutions such as Acibadem Maslak Hospital allows us to demonstrate the clinical value of OncoSil™ in world-class settings and supports our objective of expanding access to this innovative therapy for patients who urgently need new treatment options."

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Tim Luscombe & Mr. David Wood Joint Company Secretaries E: tim.luscombe@bio101.com david.wood@bio101.com T: +61 429 707 079 & +61 408 393 670	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338
--	--	---

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year¹. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Turkey, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. <https://gco.iarc.fr/en>